Global Ovarian Cancer Drugs Market By Therapy, By Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2021-2031

Table of Contents

CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO Perspective

CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.3. Porter’s five forces analysis
3.4. Top player positioning
3.5. Market dynamics
3.5.1. Drivers
3.5.2. Restraints
3.5.3. Opportunities
3.6. COVID-19 Impact Analysis on the market

CHAPTER 4: GLOBAL OVARIAN CANCER DRUGS MARKET, BY THERAPY
4.1 Overview
4.1.1 Market size and forecast
4.2 Chemotherapy
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market share analysis by country
4.3 Targeted Therapy
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market share analysis by country
4.3.4 Targeted Therapy Global Ovarian Cancer Drugs Market by Drug Class
4.4 Others
4.4.1 Key market trends, growth factors and opportunities
4.4.2 Market size and forecast, by region
4.4.3 Market share analysis by country

CHAPTER 5: GLOBAL OVARIAN CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL
5.1 Overview
5.1.1 Market size and forecast
5.2 Hospital Pharmacy
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market share analysis by country
5.3 Drug Stores and Retail Pharmacy
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market share analysis by country
5.4 Online Providers
5.4.1 Key market trends, growth factors and opportunities
5.4.2 Market size and forecast, by region
5.4.3 Market share analysis by country

CHAPTER 6: GLOBAL OVARIAN CANCER DRUGS MARKET, BY REGION
6.1 Overview
6.1.1 Market size and forecast
6.2 North America
6.2.1 Key trends and opportunities
6.2.2 North America Market size and forecast, by Therapy
6.2.3 North America Market size and forecast, by Distribution Channel
6.2.4 North America Market size and forecast, by country
6.2.4.1 U. S.
6.2.4.1.1 Key market trends, growth factors and opportunities
6.2.4.1.2 Market size and forecast, by Therapy
6.2.4.1.3 Market size and forecast, by Distribution Channel
6.2.4.2 Canada
6.2.4.2.1 Key market trends, growth factors and opportunities
6.2.4.2.2 Market size and forecast, by Therapy
6.2.4.2.3 Market size and forecast, by Distribution Channel
6.2.4.3 Mexico
6.2.4.3.1 Key market trends, growth factors and opportunities
6.2.4.3.2 Market size and forecast, by Therapy
6.2.4.3.3 Market size and forecast, by Distribution Channel
6.3 Europe
6.3.1 Key trends and opportunities
6.3.2 Europe Market size and forecast, by Therapy
6.3.3 Europe Market size and forecast, by Distribution Channel
6.3.4 Europe Market size and forecast, by country
6.3.4.1 Germany
6.3.4.1.1 Key market trends, growth factors and opportunities
6.3.4.1.2 Market size and forecast, by Therapy
6.3.4.1.3 Market size and forecast, by Distribution Channel
6.3.4.2 France
6.3.4.2.1 Key market trends, growth factors and opportunities
6.3.4.2.2 Market size and forecast, by Therapy
6.3.4.2.3 Market size and forecast, by Distribution Channel
6.3.4.3 UK
6.3.4.3.1 Key market trends, growth factors and opportunities
6.3.4.3.2 Market size and forecast, by Therapy
6.3.4.3.3 Market size and forecast, by Distribution Channel
6.3.4.4 Italy
6.3.4.4.1 Key market trends, growth factors and opportunities
6.3.4.4.2 Market size and forecast, by Therapy
6.3.4.4.3 Market size and forecast, by Distribution Channel
6.3.4.5 Spain
6.3.4.5.1 Key market trends, growth factors and opportunities
6.3.4.5.2 Market size and forecast, by Therapy
6.3.4.5.3 Market size and forecast, by Distribution Channel
6.3.4.6 Rest of Europe
6.3.4.6.1 Key market trends, growth factors and opportunities
6.3.4.6.2 Market size and forecast, by Therapy
6.3.4.6.3 Market size and forecast, by Distribution Channel
6.4 Asia-Pacific
6.4.1 Key trends and opportunities
6.4.2 Asia-Pacific Market size and forecast, by Therapy
6.4.3 Asia-Pacific Market size and forecast, by Distribution Channel
6.4.4 Asia-Pacific Market size and forecast, by country
6.4.4.1 Japan
6.4.4.1.1 Key market trends, growth factors and opportunities
6.4.4.1.2 Market size and forecast, by Therapy
6.4.4.1.3 Market size and forecast, by Distribution Channel
6.4.4.2 China
6.4.4.2.1 Key market trends, growth factors and opportunities
6.4.4.2.2 Market size and forecast, by Therapy
6.4.4.2.3 Market size and forecast, by Distribution Channel
6.4.4.3 Australia
6.4.4.3.1 Key market trends, growth factors and opportunities
6.4.4.3.2 Market size and forecast, by Therapy
6.4.4.3.3 Market size and forecast, by Distribution Channel
6.4.4.4 India
6.4.4.4.1 Key market trends, growth factors and opportunities
6.4.4.4.2 Market size and forecast, by Therapy
6.4.4.4.3 Market size and forecast, by Distribution Channel
6.4.4.5 South Korea
6.4.4.5.1 Key market trends, growth factors and opportunities
6.4.4.5.2 Market size and forecast, by Therapy
6.4.4.5.3 Market size and forecast, by Distribution Channel
6.4.4.6 Rest of Asia-Pacific
6.4.4.6.1 Key market trends, growth factors and opportunities
6.4.4.6.2 Market size and forecast, by Therapy
6.4.4.6.3 Market size and forecast, by Distribution Channel
6.5 LAMEA
6.5.1 Key trends and opportunities
6.5.2 LAMEA Market size and forecast, by Therapy
6.5.3 LAMEA Market size and forecast, by Distribution Channel
6.5.4 LAMEA Market size and forecast, by country
6.5.4.1 Brazil
6.5.4.1.1 Key market trends, growth factors and opportunities
6.5.4.1.2 Market size and forecast, by Therapy
6.5.4.1.3 Market size and forecast, by Distribution Channel
6.5.4.2 Saudi Arabia
6.5.4.2.1 Key market trends, growth factors and opportunities
6.5.4.2.2 Market size and forecast, by Therapy
6.5.4.2.3 Market size and forecast, by Distribution Channel
6.5.4.3 South Africa
6.5.4.3.1 Key market trends, growth factors and opportunities
6.5.4.3.2 Market size and forecast, by Therapy
6.5.4.3.3 Market size and forecast, by Distribution Channel
6.5.4.4 Rest of LAMEA
6.5.4.4.1 Key market trends, growth factors and opportunities
6.5.4.4.2 Market size and forecast, by Therapy
6.5.4.4.3 Market size and forecast, by Distribution Channel

CHAPTER 7: COMPANY LANDSCAPE
7.1. Introduction
7.2. Top winning strategies
7.3. Product Mapping of Top 10 Players
7.4. Competitive Dashboard
7.5. Competitive Heatmap
7.6. Key developments

CHAPTER 8: COMPANY PROFILES
8.1 F. Hoffmann-La Roche AG
8.1.1 Company overview
8.1.2 Company snapshot
8.1.3 Operating business segments
8.1.4 Product portfolio
8.1.5 Business performance
8.1.6 Key strategic moves and developments
8.2 Johnson & Johnson Services, Inc.
8.2.1 Company overview
8.2.2 Company snapshot
8.2.3 Operating business segments
8.2.4 Product portfolio
8.2.5 Business performance
8.2.6 Key strategic moves and developments
8.3 GlaxoSmithKline Plc
8.3.1 Company overview
8.3.2 Company snapshot
8.3.3 Operating business segments
8.3.4 Product portfolio
8.3.5 Business performance
8.3.6 Key strategic moves and developments
8.4 Boehringer Ingelheim International GmbH
8.4.1 Company overview
8.4.2 Company snapshot
8.4.3 Operating business segments
8.4.4 Product portfolio
8.4.5 Business performance
8.4.6 Key strategic moves and developments
8.5 Clovis Oncology
8.5.1 Company overview
8.5.2 Company snapshot
8.5.3 Operating business segments
8.5.4 Product portfolio
8.5.5 Business performance
8.5.6 Key strategic moves and developments
8.6 Abbvie Inc
8.6.1 Company overview
8.6.2 Company snapshot
8.6.3 Operating business segments
8.6.4 Product portfolio
8.6.5 Business performance
8.6.6 Key strategic moves and developments
8.7 Pfizer, Inc.
8.7.1 Company overview
8.7.2 Company snapshot
8.7.3 Operating business segments
8.7.4 Product portfolio
8.7.5 Business performance
8.7.6 Key strategic moves and developments
8.8 Merck KGaA
8.8.1 Company overview
8.8.2 Company snapshot
8.8.3 Operating business segments
8.8.4 Product portfolio
8.8.5 Business performance
8.8.6 Key strategic moves and developments
8.9 AstraZeneca
8.9.1 Company overview
8.9.2 Company snapshot
8.9.3 Operating business segments
8.9.4 Product portfolio
8.9.5 Business performance
8.9.6 Key strategic moves and developments
8.10 Amgen Inc.
8.10.1 Company overview
8.10.2 Company snapshot
8.10.3 Operating business segments
8.10.4 Product portfolio
8.10.5 Business performance
8.10.6 Key strategic moves and developments

Executive Summary

According to this report, titled, 'Global Ovarian Cancer Drugs Market,' the global ovarian cancer drugs market size was valued at $2.3 billion in 2021, and is estimated to reach $5.1 billion by 2031, growing at a CAGR of 8.4% from 2022 to 2031.

Ovarian cancer is a group of diseases that originates in the ovaries, or in the related areas of the fallopian tubes and the peritoneum. Women have two ovaries that are located in the pelvis, one on each side of the uterus. The ovaries make female hormones and produce eggs for reproduction. Women have two fallopian tubes that are a pair of long, slender tubes on each side of the uterus. Eggs pass from the ovaries through the fallopian tubes to the uterus. The peritoneum is the tissue lining that covers organs in the abdomen. When ovarian cancer is found in its early stages, treatment works best. Furthermore, the cause of ovarian cancer is not clear, but experts have identified some risk factors that may include having a family history of breast and ovarian cancer, undergoing hormone replacement therapy and being overweight.

Ovarian cancers come in a variety of different tumor types and subtypes. The most common tumour type is adenocarcinoma, and the most common subtype is serous adenocarcinoma. Most serious adenocarcinomas are high-grade (aggressively growing) tumors.

The key factors that drive the growth of the ovarian cancer drugs market size are increase in aging population of women, rise in prevalence of ovarian cancer, introduction of innovative medications and increase in government support. Moreover, upsurge in healthcare spending and amplified government funding are some of the major ovarian cancer drugs market trends. However, high cost of drug development and threat of failure are likely to hamper the growth of the ovarian cancer drugs market during the forecast period. Conversely, advancement of cancer research and personalized medicine approaches are expected to provide numerous opportunities in ovarian cancer drugs industry during the forecast period.

By therapy, the targeted therapy segment dominated the ovarian cancer drugs industry in 2021 and is expected to remain dominant during the forecast period, owing to identification of molecular targets of cancer cells, fewer adverse effects, and availability of number of targeted therapeutic. In addition, recent advances in cellular technology have contributed to improve the understanding of tumour cells and their metabolism at molecular level, which further propel the market growth of this segment.

By distribution channel, the hospital pharmacy segment held the largest ovarian cancer drugs market Share in 2021 owing to increase in prevalence of ovarian cancer and increase in number of hospitalization. Moreover, the rapid adoption of automation technologies, such as pharmacy robots, dispensing, and packaging systems is driving the segment growth.

Region wise, North America has the highest ovarian cancer drugs market share and is registering a significant CAGR during the forecast period. The dominance is due to presence of large patient population, strong presence of key players, ease of drug availability, well developed healthcare infrastructure. In addition, favorable reimbursement policies in healthcare system, higher number of research, development, & innovation activities and higher adoption of advanced therapeutics further drive the market growth. Asia-Pacific is projected to register the highest CAGR during the ovarian cancer drugs market forecast. The evolving healthcare regulatory landscape, an increase in the number of patients with ovarian cancer, and the government's emphasis on enhancing R&D capabilities for innovative drug development are the key driving factors that boost the growth of the market in the region.

KEY FINDINGS OF STUDY

On the basis of ovarian cancer drugs market analysis, the targeted therapy segment dominated the market in 2021, and is expected to continue this trend during the forecast period.

Depending on distribution channel, the hospital pharmacy segment is projected to grow at significant CAGR during the forecast period.

Region-wise, North America garnered the largest revenue share in 2021. However, Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period.

Companies Mentioned

• Abbvie Inc.
• Pfizer, Inc.
• Merck KGaA
• Astrazeneca
• F. Hoffmann-La Roche AG
• Clovis Oncology
• Amgen Inc.
• Johnson & Johnson Services, Inc.
• Boehringer Ingelheim International GmbH
• GlaxoSmithKline PLC

Methodology

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

• Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
• Scientific and technical writings for product information and related preemptions
• Regional government and statistical databases for macro analysis
• Authentic news articles and other related releases for market evaluation
• Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.